Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Odile Oberlin

Showing results (41-50 of 111) with videos related to

Pageof 12
Sort By:
Pediatric Blood & Cancer|September 3, 2013
Conservative approach in localised rhabdomyosarcoma of the bladder and prostate: results from International Society of Paediatric Oncology (SIOP) studies: malignant mesenchymal tumour (MMT) 84, 89 and 95Meriel Jenney, Odile Oberlin, Georges Audry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2011
Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapyJulia C Chisholm, Julien Marandet, Annie Rey, et al.
International Journal of Radiation Oncology, Biology, Physics|July 22, 2010
Radiation therapy and late mortality from second sarcoma, carcinoma, and hematological malignancies after a solid cancer in childhoodMarkhaba Tukenova, Catherine Guibout, Mike Hawkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2007
Extraosseous localized ewing tumors: improved outcome with anthracyclines--the French society of pediatric oncology and international society of pediatric oncologyMarie-Pierre Castex, Hervé Rubie, Michael C G Stevens, et al.
International Journal of Cancer|October 3, 2006
Concomitant chemo-radiotherapy and local dose of radiation as risk factors for second malignant neoplasms after solid cancer in childhood: a case-control studySylvie Guérin, Catherine Guibout, Akthar Shamsaldin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratificationEdoardo Missiaglia, Dan Williamson, Julia Chisholm, et al.
Pediatric Blood & Cancer|April 21, 2015
Primary cutaneous and subcutaneous Ewing sarcomaAngela Di Giannatale, Anna Maria Frezza, Marie-Cécile Le Deley, et al.
Cancer|May 26, 2007
Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphomaChristine Mauz-Körholz, Stephanie Gorde-Grosjean, Dirk Hasenclever, et al.
Cancer Chemotherapy and Pharmacology|November 20, 2012
Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcomaCormac Owens, Valerie Laurence, Lofti Benboubker, et al.
Pediatric Blood & Cancer|August 11, 2015
Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative GroupsOdile Oberlin, Annie Rey, Kenneth L B Brown, et al.
Pageof 12

Showing results (41-50 of 111) with videos related to

Sort By:
Pageof 12
Pediatric Blood & Cancer|September 3, 2013
Conservative approach in localised rhabdomyosarcoma of the bladder and prostate: results from International Society of Paediatric Oncology (SIOP) studies: malignant mesenchymal tumour (MMT) 84, 89 and 95Meriel Jenney, Odile Oberlin, Georges Audry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2011
Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapyJulia C Chisholm, Julien Marandet, Annie Rey, et al.
International Journal of Radiation Oncology, Biology, Physics|July 22, 2010
Radiation therapy and late mortality from second sarcoma, carcinoma, and hematological malignancies after a solid cancer in childhoodMarkhaba Tukenova, Catherine Guibout, Mike Hawkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2007
Extraosseous localized ewing tumors: improved outcome with anthracyclines--the French society of pediatric oncology and international society of pediatric oncologyMarie-Pierre Castex, Hervé Rubie, Michael C G Stevens, et al.
International Journal of Cancer|October 3, 2006
Concomitant chemo-radiotherapy and local dose of radiation as risk factors for second malignant neoplasms after solid cancer in childhood: a case-control studySylvie Guérin, Catherine Guibout, Akthar Shamsaldin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratificationEdoardo Missiaglia, Dan Williamson, Julia Chisholm, et al.
Pediatric Blood & Cancer|April 21, 2015
Primary cutaneous and subcutaneous Ewing sarcomaAngela Di Giannatale, Anna Maria Frezza, Marie-Cécile Le Deley, et al.
Cancer|May 26, 2007
Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphomaChristine Mauz-Körholz, Stephanie Gorde-Grosjean, Dirk Hasenclever, et al.
Cancer Chemotherapy and Pharmacology|November 20, 2012
Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcomaCormac Owens, Valerie Laurence, Lofti Benboubker, et al.
Pediatric Blood & Cancer|August 11, 2015
Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative GroupsOdile Oberlin, Annie Rey, Kenneth L B Brown, et al.
Pageof 12